A phase III randomized trial of pulse actinomycin-d versus multi-day methotrexate for the treatment of low-risk gestational trophoblastic neoplasia
Principal Investigator
Julian Schink, MD
Status
Terminated
Date Opened To Accrual
June 18 2012
Date Closed to Accrual
September 20 2016
Date of Study Termination
July 17 2020
Disease Site
Gynecologic [GY]
Other
Phase
III
Developmental Therapeutics
No
Primary Objective
To test the hypothesis that treatment with multi-day methotrexate is inferior to treatment with pulse actinomycin-D in patients with low-risk gestational trophoblastic disease with respect to complete response.
Patient Population
Patients who meet F.I.G.O. Stage I, II, or III criteria for low-risk gestational trophoblastic neoplasia (GTN): post molar GTN or choriocarcinoma.
Target Accrual
384
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.